Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Laura S M KerkmeijerRuben Y G TijssenSjoerd H HofmaRene J van der SchaafE Karin ArkenboutAuke P J D WeeversRobin P KraakYoshinobu OnumaPatrick W J C SerruysJan J PiekJan G P TijssenJosé P S HenriquesRobbert J de WinterJoanna J WykrzykowskaPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
In routine PCI practice, both Absorb BVS and Xience EES have worse clinical outcomes in diabetic patients as compared to nondiabetic patients. Throughout all clinical presentations, Absorb BVS was associated with higher rates of device thrombosis at 3-year follow-up.
Keyphrases
- end stage renal disease
- coronary artery disease
- percutaneous coronary intervention
- acute myocardial infarction
- acute coronary syndrome
- clinical practice
- ejection fraction
- chronic kidney disease
- newly diagnosed
- primary care
- healthcare
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- antiplatelet therapy
- atrial fibrillation
- pulmonary embolism
- prognostic factors
- coronary artery bypass grafting
- skeletal muscle
- patient reported outcomes
- insulin resistance
- tissue engineering
- patient reported